Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles

Area of Science:

• Pharmacology
• Drug Metabolism
• Genetics

Background:

• Cytochrome P450 2D6 (CYP2D6) is a key enzyme in drug metabolism.
• Genetic variations in CYP2D6 alleles lead to different enzyme activity levels.
• Understanding variant-specific metabolism is crucial for predicting drug efficacy and safety.

Purpose of the Study:

• To compare the metabolism of various drugs and drug candidates across different CYP2D6 variants.
• To investigate the activity of CYP2D6*17 compared to CYP2D6*1 using specific substrates.
• To determine if CYP2D6 variant activity follows a generalizable pattern.

Main Methods:

• Genetically engineered V79 cells expressing CYP2D6*1, *2, *9, and *17 variants.
• Incubation of V79 cells with bufuralol, dextromethorphan, imipramine, mianserin, sparteine, tamoxifen, haloperidol, Rec27/0110, and Rec15/2739.
• Confirmation of results using yeast microsomes expressing CYP2D6*1 and CYP2D6*17, and the inhibitor quinidine.

Main Results:

• CYP2D6*17 exhibited a distinct metabolism profile for haloperidol and Rec27/0110 compared to other substrates.
• For haloperidol and Rec27/0110, CYP2D6*17 showed equal or greater activity than the common CYP2D6*1 allele.
• Standard CYP2D6 substrates did not predict the activity of CYP2D6*17 with these specific compounds.

Conclusions:

• CYP2D6 allele activity is substrate-dependent, not governed by a universal rule.
• The metabolic profile of CYP2D6 variants can vary significantly based on the drug.
• These findings have implications for understanding individual pharmacokinetic differences and drug response.